0.39
-0.0055(-1.39%)
Currency In USD
| Previous Close | 0.4 |
| Open | 0.39 |
| Day High | 0.41 |
| Day Low | 0.39 |
| 52-Week High | 2.53 |
| 52-Week Low | 0.24 |
| Volume | 174,849 |
| Average Volume | 522,759 |
| Market Cap | 22.81M |
| PE | -0.32 |
| EPS | -1.22 |
| Moving Average 50 Days | 0.43 |
| Moving Average 200 Days | 0.9 |
| Change | -0.01 |
If you invested $1000 in BioAtla, Inc. (BCAB) since IPO date, it would be worth $12.59 as of July 02, 2025 at a share price of $0.391. Whereas If you bought $1000 worth of BioAtla, Inc. (BCAB) shares 3 years ago, it would be worth $110.94 as of July 02, 2025 at a share price of $0.391.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen
GlobeNewswire Inc.
Jun 02, 2025 12:00 PM GMT
45% overall response rate (ORR) and a 100% disease control rate (DCR) in HPV+ OPSCC patients treated with a median of 3 prior lines of therapy Marked unmet need exists in 2L+ HPV+ OPSCC patients; standard of care agents (methotrexate, docetaxel, or c
BioAtla to Participate in the Citizens Life Sciences Conference
GlobeNewswire Inc.
Apr 30, 2025 12:00 PM GMT
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, tod
BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025
GlobeNewswire Inc.
Apr 29, 2025 12:00 PM GMT
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, tod